GSK (LON:GSK) Shares Cross Above 200 Day Moving Average – Time to Sell?

GSK plc (LON:GSK) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,750.11 and traded as high as GBX 2,201. GSK shares last traded at GBX 2,186.93, with a volume of 15,071,270 shares traded.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Shore Capital Group reaffirmed a “buy” rating and issued a GBX 2,300 price objective on shares of GSK in a research report on Wednesday, February 4th. Berenberg Bank increased their price target on GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research note on Monday, November 24th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 price objective on shares of GSK in a research report on Wednesday, January 7th. UBS Group reiterated a “neutral” rating and issued a GBX 1,940 price objective on shares of GSK in a report on Friday, January 23rd. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research report on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of GBX 1,917.86.

GSK Stock Performance

The company has a fifty day moving average of GBX 1,960.71 and a two-hundred day moving average of GBX 1,750.11. The firm has a market capitalization of £88.24 billion, a price-to-earnings ratio of 16.44, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities research analysts predict that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Insider Activity at GSK

In other GSK news, insider Jonathan Symonds acquired 2,500 shares of the business’s stock in a transaction on Thursday, February 5th. The stock was purchased at an average price of GBX 2,114 per share, with a total value of £52,850. Also, insider Wendy Becker bought 3,334 shares of the stock in a transaction dated Friday, February 20th. The shares were acquired at an average cost of GBX 2,219 per share, for a total transaction of £73,981.46. Over the last three months, insiders have acquired 7,931 shares of company stock worth $16,480,489. Corporate insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.